JERUSALEM--(BUSINESS WIRE)--On its conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2012. This outlook is summarized below.
Total net sales of approximately $22 billion, consisting of total U.S. net sales of $11 billion, total European net sales of $6.6 billion, and total ROW net sales of $4.4 billion. These figures include the following major business lines: ?Generic product (including API) net sales of approximately $11.8 billion, consisting of U.S. generic sales of $5.0 billion, European generic sales of $4.0 billion, and ROW generic sales of $2.8 billion.
